1.37229
Inorganic Pyrophosphatase
EMPROVE® EXPERT
Synonym(s):
IPP, PPase
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Specific activity:
≥100 units/mL
Assay:
≥95% (SDS-PAGE)
Biological source:
Escherichia coli
Recombinant:
expressed in E. coli
biological source
Escherichia coli
Quality Level
recombinant
expressed in E. coli
grade
GMP, Halal, Kosher
product line
EMPROVE® EXPERT
assay
≥95% (SDS-PAGE)
form
aqueous solution
specific activity
≥100 units/mL
mol wt
19.7 kDa
technique(s)
in vitro transcription (IVT): suitable
suitability
suitable for (In‑vitro transcription (IVT))
application(s)
pharma/biopharma processes
pharmaceutical
foreign activity
Low endotoxin
Low bioburden
DNase: none detected
RNase: none detected
Nickase: none detected
storage temp.
-10 to -25°C
General description
mRNA therapies represent a revolutionary approach to therapeutics such as vaccines, cancer treatments, and immunotherapies, offering novel ways to treat complex diseases. As a result, global interest in mRNA manufacturing has grown, while regulatory expectations have become increasingly exacting. In this environment, manufacturers require raw materials suitable for pharmaceutical use, ensuring the highest levels of quality and purity for successful mRNA production.
In response, we have developed the high-purity Enzyme Emprove® Expert portfolio, compliant with IPEC-PQG GMP standards, to ensure batch-to-batch consistency in your mRNA manufacturing processes. These critical raw materials are accompanied by comprehensive Emprove® dossiers, providing essential regulatory support to navigate the complexities of the biopharmaceutical industry while ensuring compliance and accelerating time to market.
As part of our SAFC® portfolio, these high-quality raw materials are designed to meet the specific needs of pharma and biopharma production.
In response, we have developed the high-purity Enzyme Emprove® Expert portfolio, compliant with IPEC-PQG GMP standards, to ensure batch-to-batch consistency in your mRNA manufacturing processes. These critical raw materials are accompanied by comprehensive Emprove® dossiers, providing essential regulatory support to navigate the complexities of the biopharmaceutical industry while ensuring compliance and accelerating time to market.
As part of our SAFC® portfolio, these high-quality raw materials are designed to meet the specific needs of pharma and biopharma production.
Application
Inorganic pyrophosphatase (IPP) is an essential auxiliary enzyme used to enhance the efficiency of in vitro transcription (IVT) reactions for messenger RNA (mRNA) production. During IVT, inorganic pyrophosphate (PPi) accumulates as a reaction by-product and can inhibit RNA polymerase activity, ultimately reducing mRNA yield. IPP catalyzes the hydrolysis of PPi into inorganic phosphate, preventing product inhibition and supporting higher and more consistent transcription efficiency.
Features and Benefits
Our IVT enzyme Emprove® Expert IVT portfolio is designed to align with best-practice IVT methods for mRNA manufacturing and provides all purity requirements for reliable production of mRNA therapeutics and vaccines:
- High purity (≥95%)
- Low endotoxin and bioburden
- DNase and RNase-free
Packaging
137229.0001 / 1 mL / plastic vial
137229.0010 / 10 mL / plastic bottle
137229.0050 / 50 mL / plastic bottle
137229.0010 / 10 mL / plastic bottle
137229.0050 / 50 mL / plastic bottle
Legal Information
Emprove is a registered trademark of Merck KGaA, Darmstadt, Germany
SAFC is a registered trademark of Merck KGaA, Darmstadt, Germany
Storage Class
10 - Combustible liquids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
Regulatory Information
新产品
This item has
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.